106 related articles for article (PubMed ID: 16832603)
21. Development of an orally-administrable tumor vasculature-targeting therapeutic using annexin A1-binding D-peptides.
Nonaka M; Mabashi-Asazuma H; Jarvis DL; Yamasaki K; Akama TO; Nagaoka M; Sasai T; Kimura-Takagi I; Suwa Y; Yaegashi T; Huang CT; Nishizawa-Harada C; Fukuda MN
PLoS One; 2021; 16(1):e0241157. PubMed ID: 33406123
[TBL] [Abstract][Full Text] [Related]
22. Approaches to develop therapeutics to treat frontotemporal dementia.
Elia LP; Reisine T; Alijagic A; Finkbeiner S
Neuropharmacology; 2020 Apr; 166():107948. PubMed ID: 31962288
[TBL] [Abstract][Full Text] [Related]
23. Combination of Anti-Cancer Drugs with Molecular Chaperone Inhibitors.
Shevtsov M; Multhoff G; Mikhaylova E; Shibata A; Guzhova I; Margulis B
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31652993
[TBL] [Abstract][Full Text] [Related]
24. HIF Inhibitors: Status of Current Clinical Development.
Fallah J; Rini BI
Curr Oncol Rep; 2019 Jan; 21(1):6. PubMed ID: 30671662
[TBL] [Abstract][Full Text] [Related]
25. Histone deacetylase activity mediates acquired resistance towards structurally diverse HSP90 inhibitors.
Chai RC; Vieusseux JL; Lang BJ; Nguyen CH; Kouspou MM; Britt KL; Price JT
Mol Oncol; 2017 May; 11(5):567-583. PubMed ID: 28306192
[TBL] [Abstract][Full Text] [Related]
26. Effects of treatment with an Hsp90 inhibitor in tumors based on 15 phase II clinical trials.
Wang H; Lu M; Yao M; Zhu W
Mol Clin Oncol; 2016 Sep; 5(3):326-334. PubMed ID: 27602225
[TBL] [Abstract][Full Text] [Related]
27. Heat shock proteins in the retina: Focus on HSP70 and alpha crystallins in ganglion cell survival.
Piri N; Kwong JM; Gu L; Caprioli J
Prog Retin Eye Res; 2016 May; 52():22-46. PubMed ID: 27017896
[TBL] [Abstract][Full Text] [Related]
28. Hsp90: A New Player in DNA Repair?
Pennisi R; Ascenzi P; di Masi A
Biomolecules; 2015 Oct; 5(4):2589-618. PubMed ID: 26501335
[TBL] [Abstract][Full Text] [Related]
29. The human immunodeficiency virus protease inhibitor ritonavir is potentially active against urological malignancies.
Sato A
Onco Targets Ther; 2015; 8():761-8. PubMed ID: 25914545
[TBL] [Abstract][Full Text] [Related]
30. MTOR inhibition enhances NVP-AUY922-induced autophagy-mediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors.
Hsueh YS; Chang HH; Chiang NJ; Yen CC; Li CF; Chen LT
Oncotarget; 2014 Nov; 5(22):11723-36. PubMed ID: 25375091
[TBL] [Abstract][Full Text] [Related]
31. A 20-year-old female with hemoptysis and high blood pressure: An unusual case of papillary renal cell carcinoma.
Olaniran K; Cheng W; Pulinthanathu R
Am J Case Rep; 2014; 15():254-7. PubMed ID: 24949115
[TBL] [Abstract][Full Text] [Related]
32. Hsp90 blockers inhibit adipocyte differentiation and fat mass accumulation.
Desarzens S; Liao WH; Mammi C; Caprio M; Faresse N
PLoS One; 2014; 9(4):e94127. PubMed ID: 24705830
[TBL] [Abstract][Full Text] [Related]
33. Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions.
Jhaveri K; Ochiana SO; Dunphy MP; Gerecitano JF; Corben AD; Peter RI; Janjigian YY; Gomes-DaGama EM; Koren J; Modi S; Chiosis G
Expert Opin Investig Drugs; 2014 May; 23(5):611-28. PubMed ID: 24669860
[TBL] [Abstract][Full Text] [Related]
34. Chronic treatment with 17-DMAG improves balance and coordination in a new mouse model of Machado-Joseph disease.
Silva-Fernandes A; Duarte-Silva S; Neves-Carvalho A; Amorim M; Soares-Cunha C; Oliveira P; Thirstrup K; Teixeira-Castro A; Maciel P
Neurotherapeutics; 2014 Apr; 11(2):433-49. PubMed ID: 24477711
[TBL] [Abstract][Full Text] [Related]
35. Heat shock protein 90 and role of its chemical inhibitors in treatment of hematologic malignancies.
Ho N; Li A; Li S; Zhang H
Pharmaceuticals (Basel); 2012 Jul; 5(8):779-801. PubMed ID: 24280675
[TBL] [Abstract][Full Text] [Related]
36. Molecular mechanisms of action and therapeutic uses of pharmacological inhibitors of HIF-prolyl 4-hydroxylases for treatment of ischemic diseases.
Selvaraju V; Parinandi NL; Adluri RS; Goldman JW; Hussain N; Sanchez JA; Maulik N
Antioxid Redox Signal; 2014 Jun; 20(16):2631-65. PubMed ID: 23992027
[TBL] [Abstract][Full Text] [Related]
37. Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer.
Alcorn S; Walker AJ; Gandhi N; Narang A; Wild AT; Hales RK; Herman JM; Song DY; Deweese TL; Antonarakis ES; Tran PT
Int J Mol Sci; 2013 Jul; 14(7):14800-32. PubMed ID: 23863691
[TBL] [Abstract][Full Text] [Related]
38. Hypoxia inducible factor pathway inhibitors as anticancer therapeutics.
Burroughs SK; Kaluz S; Wang D; Wang K; Van Meir EG; Wang B
Future Med Chem; 2013 Apr; 5(5):553-72. PubMed ID: 23573973
[TBL] [Abstract][Full Text] [Related]
39. Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies.
Schenk E; Hendrickson AE; Northfelt D; Toft DO; Ames MM; Menefee M; Satele D; Qin R; Erlichman C
Invest New Drugs; 2013 Oct; 31(5):1251-6. PubMed ID: 23543109
[TBL] [Abstract][Full Text] [Related]
40. Autophagy is involved in endogenous and NVP-AUY922-induced KIT degradation in gastrointestinal stromal tumors.
Hsueh YS; Yen CC; Shih NY; Chiang NJ; Li CF; Chen LT
Autophagy; 2013 Feb; 9(2):220-33. PubMed ID: 23196876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
